Eli Lilly's Base Editor Shows Promising Results: Single Treatment Cuts LDL Cholesterol by Up to 62%

Deep News05-26 21:26

Eli Lilly has released positive Phase 1b clinical data for its investigational gene-editing therapy, VERVE-102. The treatment utilizes a one-time base editing approach, resulting in a reduction of up to 62% in patients' low-density lipoprotein cholesterol (LDL-C) levels and an 88% decrease in PCSK9 protein levels. The therapeutic effects remained stable throughout the follow-up period. Most significantly, no treatment-related serious adverse events were observed. Eli Lilly stated that it plans to initiate Phase 2 clinical trials within this year. If subsequent studies are successful, this therapy could offer a novel "one-shot, long-lasting" option for patients with conditions such as familial hypercholesterolemia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment